Table 1.
Medium score (and interquartile range) for the Nasal Obstruction Symptom Evaluation Scale (NOSE) and the Snore Outcomes Survey (SOS; selected items) at study enrollment (t1) and 30 days after radiofrequency treatment (t2); sample size and significance level of the Wilcoxon signed-rank test
| t 1 | t 2 | N | p (one-tailed) | |
|---|---|---|---|---|
| Mdn (IQR) | Mdn (IQR) | |||
| Nasal Obstruction Symtom Evaluation Scale (NOSE) | 65.00 (21.25) | 30.00 (35.00) | 30 | 0.000 |
| Snore Outcomes Survey (SOS; selected items) | 66.67 (32.29) | 47.92 (40.63) | 25 | 0.000 |
Bold—Significance level p: probability that the difference between the data collected at the measurement time points mentioned occured randomly or by chance, but is instead attributed to the low energy radiofrequency remodeling treatment (probabilty of error α)
Statistical comparisons by Wilcoxon signed-rank test; p significance level (one-tailed) concerning the difference of scores at time points t1 and t2
Mdn median, IQR interquartile range, N number of participants